1. Nicholas JW, Breman JG. Malaria and babesiosis: diseases caused by red blood cell parasites in Harrisons Principles of Internal Medicine. New York: McGraw Hill, 2005; P:1203-1212.
2. Fèvre E, Barnish G, Yamokgul P, Rooney W. Sensitivity in vitro of Plasmodium falciparum to three currently used antimalarial drugs on the western border of Thailand. Trans R Soc Trop Med Hyg. 1999; 1;93(2):180-4.
3. Hay SI, Guerra CA, Tatem AJ, Noor AM, Snow RW. The global distribution and population at risk of malaria: past, present, and future. Lancet Infect Dis. 2004; 1; 4(6):327-36.
4. WHO: World malaria report 2017. 2017. https://cdn.who.int/media/docs/default-source/Documents/world-malaria-report-2017.pdf?sfvrsn=8b7b573a_0
5. Sharma Y. Genetic alteration in drug resistance markers of Plasmodium falciparum. Indian J Med Res. 2005, Sharma Y: Genetic alteration in drug resistance markers of Plasmodium falciparum. Indian J Med Res. 2005; 1;121(1):13-22.
6. Witkowski B, Lelièvre J, Barragán MJL, et al. Increased tolerance to artemisinin in Plasmodium falciparum is mediated by a quiescence mechanism. Antimicrob Agents Chemother. 2010; 54(5):1872-7.
7. Ariey F, Witkowski B, Amaratunga C, et al. Ma L: A molecular marker of artemisinin-resistant Plasmodium falciparum malaria. Nature. 2014; 2;505(7481):50-5.
8. Dondorp AM, Nosten F, Yi P, et al. Artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med. 2009; 30;361(5):455-67.
9. Trager W, Jensen JB. Human malaria parasites in continuous culture. Science. 1976; 20;193(4254):673-5.
10. Nateghpour M, Ward S, Howells R. Induction of drug resistance in Plasmodium falciparum: an intermittent drug exposure method. Iran J Public Health. 1998; 27(1-2):43-60.
11. Chatterjee M, Ganguly S, Saha P, et al. No polymorphism in Plasmodium falciparum K13 propeller gene in clinical isolates from Kolkata, India. J Pathog. 2015; 2015:374354.
12. Hassanpour G, Mohebali M, Zeraati H, Raeisi A, Keshavarz H. Asymptomatic malaria and its challenges in the malaria elimination program in Iran: a systematic review. J Arthropod Borne Dis. 2017;11(2):172-181.
13. Mukherjee A, Bopp S, Magistrado P, et al. Artemisinin resistance without pfkelch13 mutations in Plasmodium falciparum isolates from Cambodia. Malar J. 2017; 16(1):195.
14. White NJ. Artemisinin resistance--the clock is ticking. Lancet. 2010; 18;376(9758):2051-2.
15. Eboumbou Moukoko CE, Huang F, et al. K-13 propeller gene polymorphisms isolated between 2014 and 2017 from Cameroonian Plasmodium falciparum malaria patients. PloS One. 2019; 3;14(9):e0221895.
16. Li J, Chen J, Xie D, et al. Limited artemisinin resistance-associated polymorphisms in Plasmodium falciparum K13-propeller and PfATPase6 gene isolated from Bioko Island, Equatorial Guinea. Int J Parasitol Drugs Drug Resist. 2016; 1;6(1):54-9.
17. Kwansa-Bentum B, Ayi I, Suzuki T, et al. Plasmodium falciparum isolates from southern Ghana exhibit polymorphisms in the SERCA-type PfATPase6 though sensitive to artesunate in vitro. Malar J. 2011; 10(1):1-9.
18. Alker AP, Lim P, Sem R, et al. Pfmdr1 and in vivo resistance to artesunate-mefloquine in falciparum malaria on the Cambodian–Thai border. Am J Trop Med Hyg. 2007;76(4):641-7.
19. Cui L, Wang Z, Miao J, et al. Mechanisms of in vitro resistance to dihydroartemisinin in Plasmodium falciparum. Mol Microbiol.2012; 86(1):111-28.
20. Witkowski B, Khim N, Chim P, et al. Reduced artemisinin susceptibility of Plasmodium falciparum ring stages in western Cambodia. Antimicrob Agents Chemother. 2013; 57(2):914-23.
21. Straimer J, Gnädig NF, Witkowski B, et al. K13-propeller mutations confer artemisinin resistance in Plasmodium falciparum clinical isolates. Science. 2015; 23;347(6220):428-31.
22. Rocamora F, Zhu L, Liong KY, et al. Oxidative stress and protein damage responses mediate artemisinin resistance in malaria parasites. PLoS Pathog. 2018; 14;14(3):e1006930.
23. Chavchich M, Gerena L, Peters J, Chen N, Cheng Q, Kyle DE. Role of pfmdr1 amplification and expression in induction of resistance to artemisinin derivatives in Plasmodium falciparum. Antimicrob Agents Chemother. 2010; 54(6):2455-64.
24. Heidari A, Keshavarz H. The drug resistance of Plasmodium falciparum and P. vivax in Iran: a review article. Iran J Parasitol. 2021; 16(2):173-85.
25. Heidari A, Dittrich S, Jelinek T, et al. Genotypes and in vivo resistance of Plasmodium falciparum isolates in an endemic region of Iran. Parasitol Res. 2007;100:589-92.
26. Eskandarian AA, Keshavarz H, Basco LK, Mahboudi F. Do mutations in Plasmodium falciparum dihydropteroate synthase and dihydrofolate reductase confer resistance to sulfadoxine-pyrimethamine in Iran? Trans R Soc Trop. 2002; 96(1):96-8.